Expert Point of View: Suzanne L. ­Topalian, MD


Get Permission

Suzanne L. Topalian, MD

Press conference moderator Suzanne L. ­Topalian, MD, Director of the Melanoma Program at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, said, “The approval of ipilimumab [Yervoy] as first-line therapy for advanced melanoma in 2011 was a landmark moment. This was the first drug ever to show a survival advantage in melanoma. It was also a landmark moment for immunotherapy and checkpoint blockade. Ipilimumab became the gold standard for treatment of advanced melanoma.”

She continued, “KEYNOTE-006 is the first demonstration that pembrolizumab [Keytruda] is superior to ipilimumab. We expect this study to change the treatment landscape for melanoma.”

Important areas of future research include combinations of immune therapies and optimal sequencing, she noted. ■

Disclosure: Dr. Topalian receives research grants from Bristol-Myers Squibb, and her spouse is a consultant for Merck.


Related Articles

Practice-Changing Study: Pembrolizumab Outperforms Ipilimumab in Advanced Melanoma

Pembrolizumab (Keytruda) proved superior to ipilimumab (Yervoy) for the treatment of unresectable advanced melanoma in the global phase III KEYNOTE-006 trial. Pembrolizumab significantly improved overall survival, progression-free survival, and overall response rate compared with ipilimumab, which...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.